- Policy
- Phase 2 of Shinpoong's Pyramax will be conducted again
- by Lee, Hye-Kyung Jun 16, 2022 05:57am
- Shinpoong will conduct phase 2 clinical trials of Pyramax again to prove its safety and effectiveness as a treatment for COVID-19. On the 13th, the MFDS approved a clinical trial to explore the safety and effectiveness of Pyramax in patients with mild or moderate COVID-19. Exploratory clinical trials are clinical trials conducted for the p
- Policy
- HIRA to review metformin+SGLT2+DPP4 reimb at last
- by Lee, Tak-Sun Jun 15, 2022 05:51am
- The Health Insurance Review and Assessment Service entered the final steps of its reimbursement review for a 3-drug combination therapy that contains metformin, an SLGT-2 inhibitor, and a DPP-4 inhibitor. Reimbursement of the combined use of SGLT-2 and DPP-4 class oral antidiabetic drugs had been continuously raised as an issue by academ
- Policy
- Policies at a standstill due to absence of MFDS minister
- by Lee, Jeong-Hwan Jun 15, 2022 05:50am
- With the ruling and opposition parties having difficulty coming to an agreement on the composition of the NA leadership, the prolonged policy gap in national disease control and prevention and the pharma-bio industry is intensifying due to the absence of the Minister of Health and Welfare. President Suk-Yeol Yoon’s administration had set
- Policy
- Lorviqua is about to be reimbursed
- by Lee, Tak-Sun Jun 15, 2022 05:50am
- It is known that Lorviqua, a third-generation ALK-inhibiting non-small cell lung cancer treatment, is on the verge of insurance benefits through drug price negotiations. As a result, new treatment options are expected to be created for patients who have not seen any effect even if they use first and second-generation treatments. The drug w
- Policy
- MFDS reviews EUA of COVID-19 prevention drug Evusheld
- by Lee, Hye-Kyung Jun 14, 2022 06:04am
- The emergency use authorization review for AstraZeneca’s COVID-19 preventive antibody therapy ‘Evusheld’ has begun in Korea. The Ministry of Food and Drug Safety (Minister Yu-Kyoung Oh) announced on the 10th that the ministry has started reviewing the emergency use authorization of Evusheld per request by the Korea Disease Control and
- Policy
- Yoon Gov should increase bio-health investment by 15% per yr
- by Lee, Jeong-Hwan Jun 14, 2022 06:04am
- Professor Park Eun-chul said, "We need to provide intensive support for disaster medical expenses after breaking away from the Moon administration." In order for the Yoon Seok-yeol government to innovate health care, it was suggested that the bio-health government's investment ratio should be drastically increased by more than 15% every ye
- Policy
- A petition has been filed for public consent to Enhurtu
- by Lee, Jeong-Hwan Jun 13, 2022 05:55am
- A petition for public consent has been filed to urge the health insurance coverage of HER2 (Human Epithelial Cell Growth Factor Receptor 2) low-expression breast cancer treatment Enhurtu, which is set to be approved for marketing in Korea. The petitioner, who recently filed a petition through the National Assembly, introduced to the Yoon Seok
- Policy
- Novartis' new adult leukemia drug Scemblix has been approved
- by Lee, Hye-Kyung Jun 13, 2022 05:54am
- Scemblix, a treatment for Ph+ CML adult patients, has obtained domestic permission. The MFDS approved Scemblix 20mg and Scemblix 40mg applied by Novartis on the 9th. Scemblix is used in the treatment of chronic Ph+ CML adult patients who have previously been treated with two or more TKI. The efficacy was based on MMR and Cytogenetic Re
- Policy
- The risk group for COVID-19 depression was 18.5%, down
- by Lee, Jeong-Hwan Jun 13, 2022 05:54am
- The COVID-19 depression risk group surveyed in the first quarter of this year was 18.5%, down from 22.8% in March last year. It is still high compared to 3.2% in 2019, before COVID-19, and the government plans to push for COVID-19 psychological support for daily recovery. On the 3rd, the MOHW made the announcement at a regular briefing on COV
- Policy
- Govt skeptical about using existing vaccines on monkeypox
- by Lee, Jeong-Hwan Jun 9, 2022 06:25am
- The government has said that the use of licensed human smallpox vaccines, antivirals, or vaccinia immune globulin intravenous (VIGIV) to prevent the domestic outbreak of monkeypox should be carefully considered in terms of efficacy and safety. In particular, the authorities explained there is a plan to study whether the 3rd generation sma
